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S U M M A R Y
The development of novel tuberculosis (TB) multi-drug regimens that are more efﬁcacious and of shorter
duration requires a robust drug development pipeline. Advances in quantitative modeling and
simulation can be used to maximize the utility of patient-level data from prior and contemporary clinical
trials, thus optimizing study design for anti-TB regimens. This perspective article highlights the work of
seven project teams developing ﬁrst-in-class translational and quantitative methodologies that aim to
inform drug development decision-making, dose selection, trial design, and safety assessments, in order
to achieve shorter and safer therapies for patients in need. These tools offer the opportunity to evaluate
multiple hypotheses and provide a means to identify, quantify, and understand relevant sources of
variability, to optimize translation and clinical trial design. When incorporated into the broader
regulatory sciences framework, these efforts have the potential to transform the development paradigm
for TB combination development, as well as other areas of global health.
 2016 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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461. Introduction
 In 2016, tuberculosis (TB) remains the leading worldwide cause
of death due to an infectious disease. It is a condition that impacts
one-third of the world’s population and there are approximately
1.5 million TB-related deaths worldwide each year.1 There is no
question that a more efﬁcacious and shorter duration therapeutic
treatment for TB is needed, and that its development should be a
global priority. However, the development of such a therapy is a
tall order, given that the treatment of this disease requires a multi-
drug regimen and that there are issues related to tolerability and
the emergence of resistance for all TB drugs. Therefore, an entirely
novel multi-drug regimen is required to overcome these barriers
and improve the lives of patients suffering from this disease.
The development of this novel regimen will require a robust
drug development pipeline, as well as an improved drug
development process to advance the new therapeutic candidates.
Such a process needs tools to inform critical decisions in the
complex regimen development pathway. Two exciting new
therapeutic advancements emerged in 2012 and 2014 with the47
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creativecommons.org/licenses/by-nc-nd/4.0/).accelerated conditional approvals of both bedaquiline2 and
delamanid. These novel drugs hold the promise of optimized
therapies and outcomes for patients with the most challenging
drug-resistant forms of the disease, but their utility could be
jeopardized by combining them with older, less effective drugs.
The TB community also has an opportunity to learn from and
improve the design of complex multi-drug studies by leveraging
the data from three phase III quinolone containing trials that failed
to meet their expected endpoints.3–5
Since its inception in 2010, the Critical Path to TB Drug
Regimens (CPTR) Initiative, a global public–private partnership,
has keenly focused on accelerating the development of an entirely
novel, shorter duration therapy for TB.6 A core element of the CPTR
strategy is the development, validation, and reﬁnement of a suite
of pre-clinical, translational methodologies and quantitative drug
development platforms. These efforts are focused on optimizing
the translation of novel TB drugs in development and informing the
study design and enrichment of complex combination clinical
trials (Figure 1). This holistic approach is designed to integrate
learnings from experiment-level and patient-level contemporary
data, including pre-clinical and clinical studies. These data are
integrated using the Clinical Trial Data Interchange Standards
Consortium (CDISC) Therapeutic Area Data Standard for TB, as
described in Figure 2.7 This ﬁgure also describes other componentsosis drug regimen development through innovative quantitative
s (2016), http://dx.doi.org/10.1016/j.ijid.2016.10.008
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Figure 1. CPTR comprehensive approach to optimizing translational understanding of new TB drugs and regimens.
Figure 2. CPTR data collaboration platform.
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IJID 2739 1–4 the CPTR data collaboration programs, including the Platform for
e Aggregation of Clinical Trials (TB-PACTS) and TB Relational
quencing Data Platform (ReSeqTB).8,9 These integrated data are
ing used to develop ﬁrst-in-class translational methodologies,
presented by the seven project teams described below.
 Learning from the collective TB drug development
perience through the model-based meta-analysis of phase III
inolone clinical trials: informing the path forward
CPTR and the World Health Organization (WHO) Global TB
ogramme have convened leaders of recent major TB clinical trials
d key subject matter experts. This team has reviewed key
dings from the phase III trials of ﬂuoroquinolone-containing
ortened regimens for drug-susceptible TB (OFLOTUB, REMox,
faquin) that were conducted over the last decade, and integrated
ese ﬁndings into TB-PACTS. The intent is to extract key lessons
m the TB-PACTS platform for future TB trial design, including
e analysis of endpoints of treatment outcome for the selection of
w regimens to be tested in phase III clinical trials, the statistical
ethods for assessment of non-inferiority, the incorporation of
armacokinetic/pharmacodynamic (PK/PD) parameters into pri-
ary analyses, and the need for improved knowledge of the
riability in patient response to treatment. The TB-PACTS
tabase will also be used to determine whether there is aPlease cite this article in press as: Hanna D, et al. Advancing tubercu
translational pharmacology methods and approaches. Int J Infect Dpredictable linkage between pathogen load dynamics and clini-
cally relevant endpoints in TB clinical trials. A framework for a
regulatory-oriented disease progression modeling analysis that
links pathogen dynamics over time (i.e., biomarker of drug
response) with clinically relevant endpoints will be developed.
The pathogen load dynamics model is being advanced to enable the
addition of a drug biomarker model and its application for the
development of new therapies against TB. The link to clinically
relevant endpoints is aimed at optimizing drug development
decisions.
3. Mechanistic systems pharmacology model to link target
selection with mechanisms of action and immune response:
improving discovery-to-development translation
Given the complexity of TB disease and drug treatment and the
lack of optimal clinical endpoints, a translational systems
pharmacology framework is being developed that integrates
in silico models of TB disease progression with immune and drug
response. This mechanistic model is based on non-clinical and
clinical data, which are ultimately needed to inform TB treatment
optimization and drug development. The objective of this work is
to combine interdisciplinary systems biology and systems
pharmacology models to formally characterize drug-host-bacte-
ria-infected cell interactions Q4during TB infection–an essential steplosis drug regimen development through innovative quantitative
is (2016), http://dx.doi.org/10.1016/j.ijid.2016.10.008
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IJID 2739 1–4towards maximizing the efﬁcacy and shortening the treatment
duration of novel TB regimens (Figure 2). The direct outcome of this
project is the development of a translational TB drug development
platform that will serve as a tool to optimize the study design of
key pre-clinical and clinical trials, leading to a signiﬁcantly shorter
drug development time for new TB regimens.
4. Pre-clinical quantitative exposure–response modeling using
the in vitro hollow ﬁber system for TB (HFS-TB) to improve
translation
Selecting the drug and dose to advance from the pre-clinical
study into early clinical studies is made more complex when
including multiple new agents. The CPTR partnership successfully
quantiﬁed the predictive accuracy of the HFS-TB for supporting
early drug development and dosing, and qualiﬁed this tool with the
European Medicines Agency (EMA) through a robust evidence-
based methodology.10–14 The partnership between the CPTR
expert team and Baylor University is progressing work with the
HFS-TB system to proactively assess the performance of novel TB
drugs and drug regimens.
5. Physiologically based pharmacokinetic model for TB to
understand the distribution of drug in the TB-infected lung
The Simcyp physiologically based pharmacokinetic (PBPK)
platform,15 a leading tool used widely by industry and regulators,
is intended to optimize the design of clinical studies for multiple
indications. CPTR, in partnership with Simcyp, developed a TB-
speciﬁc set of models and compound ﬁles intended to inform the
design of ﬁrst-in-human studies that will simultaneously evaluate
the exposure and efﬁcacy of novel anti-TB combination regimens
of up to four drugs, including their metabolites. This collection of
models comprises a comprehensive PBPK model of the TB-infected
lung (which includes relevant aspects of drug distribution into
granulomatous lesions), a compound library for standard-of-care
drugs (with metabolites) as well as recently approved drugs, and a
virtual South African population, which captures relevant genetic
variants and TB-related physiological changes that affect drug
distribution in this population.14 With the integration of these
components into Simcyp version 16 (a recognized and best-in-
class modeling and simulation platform), development teams and
regulators evaluating novel TB regimens will have a robust tool to
optimize clinical trial design for ﬁrst-in-human as well as drug–
drug interaction studies.
6. Cardiac risk assessment program to assess increased risk
with TB drug regimen development
Drug-induced torsades de pointes (TdP) has been a major cause
for the withdrawal of drugs approved for marketing.16 The
potential for cardiovascular risk is increased when multiple drugs
must be combined in a complex TB drug regimen.17 In order to
optimize predictions of clinically observed electrophysiological
effects of existing and novel TB drugs based on pre-clinical data on
ion channel activity, CPTR has partnered with Simcyp scientists to
develop a model-based risk-stratiﬁcation algorithm with a user-
friendly interface. This platform integrates ion channel activity
data with drug exposure information, to predict the potential risk
of drug-induced TdP that existing and novel TB drugs may pose.
This tool is intended to optimize the safety decision-making
process for TB drug development. An in silico modeling and
simulation approach that integrates electrocardiogram changes
beyond QT prolongation is now available as an actionable tool for
optimizing the cardiac safety assessment of TB drugs and drugs for
other indications.18 This approach allows for the optimization ofPlease cite this article in press as: Hanna D, et al. Advancing tubercul
translational pharmacology methods and approaches. Int J Infect Diearly screening as well as testing of clinical scenarios. Pre-clinical
and clinical development teams can use this quantitative-based set
of estimates to inform the safety of single drug and drug regimen
development.
7. Liquid culture and quantitative assessment of time-to-
positivity to support the development of a disease progression
model and clinical trial simulation tool for TB
With the development of liquid media-based culture measures
of pathogen load, the time-to-detection (TTD), also known as time-
to-positivity (TTP), has emerged as an important assessment of
patient progress during therapy. TTP represents the time to
detectable growth of Mycobacterium tuberculosis in liquid media
culture. TTP has several technical advantages over other methods,
such as colony-forming unit (CFU) quantiﬁcation from cultures in
solid medium, including reduced variability and easier technical
requirements. In a ﬁrst stage, this project has developed a
structural model that identiﬁes and quantiﬁes the most relevant
sources of variability and interpretable parameters for the
longitudinal trajectory of TTP. In a second stage, a model that
links the interpretable parameters of TTP progression with
clinically relevant endpoints in the REMox study is being
developed. These models will provide a quantitative platform to
inform decision-making when development teams are faced with
choosing to advance novel regimens from phase II testing into
phase III testing.
8. Population pharmacokinetic/pharmacodynamic (PK/PD)
models for standard-of-care TB regimens
This project has explored PK/PD data, with therapeutic drug
monitoring practiced in a ‘real-world’ clinical setting, in order to
optimize dosing for ﬁrst-line drugs in patients with active disease.
An equivalent population PK/PD understanding for second-line
drugs for patients with active disease will also be developed. These
models will provide quantitative dosing recommendations for
ﬁrst- and second-line TB regimens.
9. Conclusions
Improving the translational performance of new TB drugs will
be a foundational element to accelerate the development of an
entirely novel, shorter-duration regimen for TB. The CPTR Initiative
and its partners are committed to optimizing the design and
execution of studies to evaluate novel TB regimens, by creating
robust quantitative drug development platforms that are fully
validated (Figure 3). These platforms are based on the integration
of legacy and contemporary pre-clinical and clinical trial data. Each
of the quantitative drug development platforms described,
including a laboratory manual to support in vitro HFS-TB
experimental design and execution, will be made publically and
freely available to drug developers and to the TB research
community.
The development of these quantitative drug development
platforms, together with user-friendly interfaces, is envisioned to
optimize individualized dosing, the design of studies, and
mechanistic models of pathophysiological processes. With these
tools, the TB drug development ﬁeld can enter the twenty-ﬁrst
century and apply sophisticated technology and resources.
Modern drug development and medical practice, especially
when it relates to global health issues, demands the optimal
evidence for treatments, beyond limited empirical evidence
provided by individual controlled trials. Evidence-based analysis
must go further than the simplistic statistical inference for primary
endpoints of individual trials and requires data aggregation andosis drug regimen development through innovative quantitative
s (2016), http://dx.doi.org/10.1016/j.ijid.2016.10.008
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Figure 3. CPTR quantitative medicine approach to address key gaps in the TB drug development process.
D. Hanna et al. / International Journal of Infectious Diseases xxx (2016) xxx–xxx4
G Model
IJID 2739 1–4rresponding analysis of multiple trials without the limitations
posed by systematic reviews. The tools described here offer the
portunity to evaluate multiple hypotheses and include a myriad
 designs to evaluate such hypotheses. These platforms provide a
eans to identify, quantify, and understand relevant sources of
riability, and to optimize translation and clinical trial design.
This effort, incorporated into a regulatory sciences framework
at allows a rigorous and transparent regulatory review process,
s the potential to transform the paradigm not just for TB
mbination drug development, but also for other areas of global
alth.
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